Mateusz Gadzina
Mateusz Gadzina has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Golec
Górnośląskie Centrum Medyczne im. Prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland
10 shared publications - Emilia Koziara
Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA im. Sierżanta Grzegorza Załogi w Katowicach, Katowice, Poland
10 shared publications - Julia Gawlak
Szpital Specjalistyczny im. Jędrzeja Śniadeckiego w Nowym Sączu, Nowy Sącz, Poland
10 shared publications - Karolina Figiel
Szpital Powiatowy w Chrzanowie, Chrzanów, Poland
10 shared publications - Maciej Krzesimir Kuświk
Poznan University of Medical Sciences: Poznan
10 shared publications - Mateusz Gawin
Sosnowiecki Szpital Miejski sp. z o. o. w restrukturyzacji, Sosnowiec, Poland
10 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
THE IMPACT OF MENTAL DISORDERS AND PSYCHIATRIC TREATMENT ON THE OCCURRENCE AND COURSE OF TAKOTSUBO SYNDROME - REVIEW
The aim of this review was to summarize existing knowledge on pathophysiology and analyze the influence of mental health disorders and psychiatric treatment on the occurrence and course of Takotsubo syndrome (TTS). This review paper was based on resources available in the PubMed database; articles were identified using the following keywords: [takotsubo] + [SNRI; SSRI; ECT; psychotherapy; anxiolytics; neuroleptics]. Additionally, a manual search of the literature cited in the articles was conducted. In order that we could treat TTS properly, we need to know its pathophysiology. The current approach regards a combination of various pathophysiological mechanisms rather than one mechanism alone. Although firstly considered as “stress” or “catecholamine”, Takotsubo cardiomyopathy is more than a simple reaction to stress or catecholamine surge. Novel data indicate a complex interplay between endothelial dysfunction, inflammatory, hormones and neurotransmitters. That leads us to the conclusion that we should treat it interdisciplinary. As there are currently no specific treatments for Takotsubo syndrome, a niche for neurocardiology is emerging. This could lead to developing new management approaches, including broader application of cognitive behavioral therapy and cooperation between cardiologists and psychiatrists.
- 23 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessTHE IMPACT OF MENTAL DISORDERS AND PSYCHIATRIC TREATMENT ON THE OCCURRENCE AND COURSE OF TAKOTSUBO SYNDROME - REVIEW
The aim of this review was to summarize existing knowledge on pathophysiology and analyze the influence of mental health disorders and psychiatric treatment on the occurrence and course of Takotsubo syndrome (TTS). This review paper was based on resources available in the PubMed database; articles were identified using the following keywords: [takotsubo] + [SNRI; SSRI; ECT; psychotherapy; anxiolytics; neuroleptics]. Additionally, a manual search of the literature cited in the articles was conducted. In order that we could treat TTS properly, we need to know its pathophysiology. The current approach regards a combination of various pathophysiological mechanisms rather than one mechanism alone. Although firstly considered as “stress” or “catecholamine”, Takotsubo cardiomyopathy is more than a simple reaction to stress or catecholamine surge. Novel data indicate a complex interplay between endothelial dysfunction, inflammatory, hormones and neurotransmitters. That leads us to the conclusion that we should treat it interdisciplinary. As there are currently no specific treatments for Takotsubo syndrome, a niche for neurocardiology is emerging. This could lead to developing new management approaches, including broader application of cognitive behavioral therapy and cooperation between cardiologists and psychiatrists.
- Open Access
- 23 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
DIAGNOSTIC PITFALLS AND THERAPEUTIC CHALLENGES IN HYPONATREMIA IN ADULTS: A SYSTEMATIC REVIEW
Hyponatremia is the most common disorder of water and electrolyte balance in adult clinical practice and remains a frequent cause of diagnostic uncertainty and treatment-related harm. Although the definition of hyponatremia is straightforward, its interpretation requires assessment of tonicity, chronicity, symptoms, volume status, renal water handling, medications, endocrine disease, and the risk of overly rapid correction. This systematic review summarizes current evidence on diagnostic pitfalls and therapeutic challenges in adult hyponatremia, with particular emphasis on hypotonic hyponatremia, syndrome of inappropriate antidiursis, thiazide-associated hyponatremia and severe symptomatic presentations. PubMed/MEDLINE and PubMed Central were searched for English-language publications concerning adult hyponatremia, diagnostic pathways, correction strategies, and treatment complications. Clinical guidelines, reviews, systematic reviews, randomized trials, and observational studies were included. The literature indicates that common errors include failure to exclude pseudohyponatremia or hypertonic hyponatremia, overreliance on clinical volume assessment, delayed measurement of urine osmolality and urine sodium, under-recognition of drug-induced causes, and inadequate monitoring during therapy. Therapeutic challenges include balancing urgent treatment of cerebral edema against prevention of osmotic demyelination, managing unpredictable water diuresis, and individualizing therapy in SIAD, heart failure, cirrhosis and thiazide-associated disease. A structured, physiology-based approach can improve diagnostic accuracy and reduce avoidable harm.
- 23 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessDIAGNOSTIC PITFALLS AND THERAPEUTIC CHALLENGES IN HYPONATREMIA IN ADULTS: A SYSTEMATIC REVIEW
Hyponatremia is the most common disorder of water and electrolyte balance in adult clinical practice and remains a frequent cause of diagnostic uncertainty and treatment-related harm. Although the definition of hyponatremia is straightforward, its interpretation requires assessment of tonicity, chronicity, symptoms, volume status, renal water handling, medications, endocrine disease, and the risk of overly rapid correction. This systematic review summarizes current evidence on diagnostic pitfalls and therapeutic challenges in adult hyponatremia, with particular emphasis on hypotonic hyponatremia, syndrome of inappropriate antidiursis, thiazide-associated hyponatremia and severe symptomatic presentations. PubMed/MEDLINE and PubMed Central were searched for English-language publications concerning adult hyponatremia, diagnostic pathways, correction strategies, and treatment complications. Clinical guidelines, reviews, systematic reviews, randomized trials, and observational studies were included. The literature indicates that common errors include failure to exclude pseudohyponatremia or hypertonic hyponatremia, overreliance on clinical volume assessment, delayed measurement of urine osmolality and urine sodium, under-recognition of drug-induced causes, and inadequate monitoring during therapy. Therapeutic challenges include balancing urgent treatment of cerebral edema against prevention of osmotic demyelination, managing unpredictable water diuresis, and individualizing therapy in SIAD, heart failure, cirrhosis and thiazide-associated disease. A structured, physiology-based approach can improve diagnostic accuracy and reduce avoidable harm.
- Open Access
- 21 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and a profound economic burden on healthcare systems. This review evaluates the clinical efficacy, safety profile, and neurobiological mechanisms of psilocybin, a serotonergic psychedelic, as a targeted intervention for TRD. Current neurobiological evidence indicates that psilocybin, upon conversion to its active metabolite psilocin, acts primarily as a 5-HT2A receptor agonist. This mechanism promotes rapid structural neuroplasticity and modulates the aberrant functional connectivity characteristic of severe depression. Recent randomized clinical trials demonstrate that psilocybin, when administered in controlled settings with psychological support, produces rapid and clinically significant reductions in depressive symptoms. Comparative data indicate that its therapeutic efficacy is at least comparable to standard first-line treatments, such as SSRIs, while frequently offering a faster onset of action. Regarding safety, psilocybin is generally well-tolerated in clinical environments; adverse events are typically mild to moderate and transient. However, the strict requirement for concurrent psychological support and rigorous psychiatric screening highlights a clinical complexity distinct from traditional pharmacotherapies. Overall, current evidence indicates that psilocybin is a promising intervention for TRD with a manageable safety profile in controlled settings. Nevertheless, large-scale, long-term randomized trials are required to determine the durability of its effects and to establish standardized treatment protocols.
- 21 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessEFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and a profound economic burden on healthcare systems. This review evaluates the clinical efficacy, safety profile, and neurobiological mechanisms of psilocybin, a serotonergic psychedelic, as a targeted intervention for TRD. Current neurobiological evidence indicates that psilocybin, upon conversion to its active metabolite psilocin, acts primarily as a 5-HT2A receptor agonist. This mechanism promotes rapid structural neuroplasticity and modulates the aberrant functional connectivity characteristic of severe depression. Recent randomized clinical trials demonstrate that psilocybin, when administered in controlled settings with psychological support, produces rapid and clinically significant reductions in depressive symptoms. Comparative data indicate that its therapeutic efficacy is at least comparable to standard first-line treatments, such as SSRIs, while frequently offering a faster onset of action. Regarding safety, psilocybin is generally well-tolerated in clinical environments; adverse events are typically mild to moderate and transient. However, the strict requirement for concurrent psychological support and rigorous psychiatric screening highlights a clinical complexity distinct from traditional pharmacotherapies. Overall, current evidence indicates that psilocybin is a promising intervention for TRD with a manageable safety profile in controlled settings. Nevertheless, large-scale, long-term randomized trials are required to determine the durability of its effects and to establish standardized treatment protocols.
- Open Access
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
BEYOND CREATININE: THE ROLE OF EMERGING BIOMARKERS IN EARLY DETECTION OF ACUTE KIDNEY INJURY IN ADULTS: A SYSTEMATIC REVIEW
Acute kidney injury (AKI) is a common clinical syndrome associated with increased morbidity, mortality, length of hospitalization, and long-term risk of chronic kidney disease. In routine practice, AKI is still diagnosed primarily by changes in serum creatinine concentration and urine output. Although these criteria are standardized and clinically useful, they are imperfect markers of early kidney injury because creatinine rises only after a fall in filtration has occurred and urine output is influenced by hemodynamics, medications, fluid balance, and measurement accuracy. This systematic literature review evaluates the role of emerging biomarkers in the early detection and risk stratification of AKI in adults, with particular emphasis on neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), liver-type fatty acid-binding protein (L-FABP), cystatin C, and the cell-cycle arrest biomarker combination tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 ([TIMP-2]*[IGFBP7]). The reviewed literature suggests that biomarkers may identify tubular stress or injury earlier than conventional criteria, support risk stratification in selected high-risk populations, and help distinguish functional decline from structural damage. However, heterogeneity of populations, assay platforms, timing of sampling, thresholds, and reference standards limits routine implementation. Biomarkers are best understood as adjuncts to clinical assessment rather than replacements for standard diagnostic criteria.
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessBEYOND CREATININE: THE ROLE OF EMERGING BIOMARKERS IN EARLY DETECTION OF ACUTE KIDNEY INJURY IN ADULTS: A SYSTEMATIC REVIEW
Acute kidney injury (AKI) is a common clinical syndrome associated with increased morbidity, mortality, length of hospitalization, and long-term risk of chronic kidney disease. In routine practice, AKI is still diagnosed primarily by changes in serum creatinine concentration and urine output. Although these criteria are standardized and clinically useful, they are imperfect markers of early kidney injury because creatinine rises only after a fall in filtration has occurred and urine output is influenced by hemodynamics, medications, fluid balance, and measurement accuracy. This systematic literature review evaluates the role of emerging biomarkers in the early detection and risk stratification of AKI in adults, with particular emphasis on neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), liver-type fatty acid-binding protein (L-FABP), cystatin C, and the cell-cycle arrest biomarker combination tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 ([TIMP-2]*[IGFBP7]). The reviewed literature suggests that biomarkers may identify tubular stress or injury earlier than conventional criteria, support risk stratification in selected high-risk populations, and help distinguish functional decline from structural damage. However, heterogeneity of populations, assay platforms, timing of sampling, thresholds, and reference standards limits routine implementation. Biomarkers are best understood as adjuncts to clinical assessment rather than replacements for standard diagnostic criteria.
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
THE IMPACT OF ENDOGENOUS AND EXOGENOUS SEX HORMONES ON THE COURSE OF PORPHYRIA IN WOMEN: A NARRATIVE REVIEW
Porphyrias are a group of metabolic diseases caused by an impairment of the heme synthesis pathway, resulting in the accumulation of heme precursors. First symptoms usually occur during puberty and can be triggered by a range of factors such as drugs, alcohol, fasting, infection, and, most importantly for this study, hormonal changes. Women in the reproductive age are known to be the main group presenting with porphyria symptoms (1.5–2.5 times more frequent in women than in men) mainly due to higher concentrations of steroid hormones, particularly progesterone. Hormonal fluctuations associated with the menstrual cycle are the most commonly identified trigger causing an AIP attack in female patients. Pregnancy and exogenous hormone administration may also precipitate attacks in susceptible individuals, although there is considerable interindividual variability, and the underlying mechanisms remain incompletely understood. This review summarizes existing knowledge on hormonal changes induced by the menstrual cycle, pregnancy, hormonal contraception, and GnRH agonists in women diagnosed with porphyria. It compares it with the conclusions reached by the IPNET panelists in the newly published guidelines, released in May 2026. The available evidence, derived mainly from retrospective studies, small cohorts, and case reports, indicates that endogenous and exogenous hormones can have a major impact on susceptible women with porphyria. Most data confirmed that the use of oral contraceptives appears to carry the highest risk of precipitating attacks, whereas levonorgestrel-releasing IUDs seem to be better tolerated. GnRH agonist therapy proved highly effective and significantly safer than hormonal contraception in the treatment of recurrent cycle-related porphyria, although it requires add-back therapy, posing a threat itself. Despite recent advances and the publication of IPNET recommendations, high-quality evidence remains limited. Further prospective studies are required to establish evidence-based recommendations for hormonal management and contraception in women with acute hepatic porphyrias.
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessTHE IMPACT OF ENDOGENOUS AND EXOGENOUS SEX HORMONES ON THE COURSE OF PORPHYRIA IN WOMEN: A NARRATIVE REVIEW
Porphyrias are a group of metabolic diseases caused by an impairment of the heme synthesis pathway, resulting in the accumulation of heme precursors. First symptoms usually occur during puberty and can be triggered by a range of factors such as drugs, alcohol, fasting, infection, and, most importantly for this study, hormonal changes. Women in the reproductive age are known to be the main group presenting with porphyria symptoms (1.5–2.5 times more frequent in women than in men) mainly due to higher concentrations of steroid hormones, particularly progesterone. Hormonal fluctuations associated with the menstrual cycle are the most commonly identified trigger causing an AIP attack in female patients. Pregnancy and exogenous hormone administration may also precipitate attacks in susceptible individuals, although there is considerable interindividual variability, and the underlying mechanisms remain incompletely understood. This review summarizes existing knowledge on hormonal changes induced by the menstrual cycle, pregnancy, hormonal contraception, and GnRH agonists in women diagnosed with porphyria. It compares it with the conclusions reached by the IPNET panelists in the newly published guidelines, released in May 2026. The available evidence, derived mainly from retrospective studies, small cohorts, and case reports, indicates that endogenous and exogenous hormones can have a major impact on susceptible women with porphyria. Most data confirmed that the use of oral contraceptives appears to carry the highest risk of precipitating attacks, whereas levonorgestrel-releasing IUDs seem to be better tolerated. GnRH agonist therapy proved highly effective and significantly safer than hormonal contraception in the treatment of recurrent cycle-related porphyria, although it requires add-back therapy, posing a threat itself. Despite recent advances and the publication of IPNET recommendations, high-quality evidence remains limited. Further prospective studies are required to establish evidence-based recommendations for hormonal management and contraception in women with acute hepatic porphyrias.
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
THE ROLE OF OBESITY-RELATED CHRONIC INFLAMMATION IN THE PATHOGENESIS AND SEVERITY OF ASTHMA IN ADULTS: A SYSTEMATIC REVIEW
Obesity and asthma are common chronic conditions that frequently coexist in adults and contribute to a substantial clinical and public health burden. Although excess body weight affects asthma through mechanical effects on lung volumes and airway closure, current evidence increasingly supports the role of obesity-related chronic low-grade inflammation as a central mechanism linking obesity with asthma development, severity, symptom burden, exacerbation risk, and therapeutic response. This systematic review summarizes contemporary evidence on the role of adipose-tissue inflammation, adipokines, cytokine signaling, metabolic dysfunction, oxidative stress, and immune dysregulation in the pathogenesis and clinical expression of obesity-related asthma in adults. A structured literature search was performed using major biomedical databases, with priority given to systematic reviews, meta-analyses, clinical reviews, cohort studies, mechanistic studies, and current asthma guidelines. The available literature indicates that obesity-related asthma is not a single uniform phenotype but a heterogeneous clinical entity involving overlapping inflammatory, metabolic, mechanical, and behavioral pathways. Increased systemic inflammatory activity, altered leptin and adiponectin signaling, elevated interleukin-6, neutrophilic airway inflammation, insulin resistance, and comorbidities such as obstructive sleep apnea and gastroesophageal reflux may all contribute to worse asthma control. Clinical management should therefore extend beyond inhaled pharmacotherapy and include assessment of obesity as a treatable trait, weight management, comorbidity screening, lifestyle intervention, and individualized evaluation of inflammatory phenotype. Future studies should clarify causal mechanisms and determine which interventions most effectively improve asthma outcomes in adults with obesity.
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessTHE ROLE OF OBESITY-RELATED CHRONIC INFLAMMATION IN THE PATHOGENESIS AND SEVERITY OF ASTHMA IN ADULTS: A SYSTEMATIC REVIEW
Obesity and asthma are common chronic conditions that frequently coexist in adults and contribute to a substantial clinical and public health burden. Although excess body weight affects asthma through mechanical effects on lung volumes and airway closure, current evidence increasingly supports the role of obesity-related chronic low-grade inflammation as a central mechanism linking obesity with asthma development, severity, symptom burden, exacerbation risk, and therapeutic response. This systematic review summarizes contemporary evidence on the role of adipose-tissue inflammation, adipokines, cytokine signaling, metabolic dysfunction, oxidative stress, and immune dysregulation in the pathogenesis and clinical expression of obesity-related asthma in adults. A structured literature search was performed using major biomedical databases, with priority given to systematic reviews, meta-analyses, clinical reviews, cohort studies, mechanistic studies, and current asthma guidelines. The available literature indicates that obesity-related asthma is not a single uniform phenotype but a heterogeneous clinical entity involving overlapping inflammatory, metabolic, mechanical, and behavioral pathways. Increased systemic inflammatory activity, altered leptin and adiponectin signaling, elevated interleukin-6, neutrophilic airway inflammation, insulin resistance, and comorbidities such as obstructive sleep apnea and gastroesophageal reflux may all contribute to worse asthma control. Clinical management should therefore extend beyond inhaled pharmacotherapy and include assessment of obesity as a treatable trait, weight management, comorbidity screening, lifestyle intervention, and individualized evaluation of inflammatory phenotype. Future studies should clarify causal mechanisms and determine which interventions most effectively improve asthma outcomes in adults with obesity.
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
OSTEOPOROSIS IN ADULTS: DIAGNOSIS, PREVENTION, AND TREATMENT – A NARRATIVE REVIEW
Objective: To synthesize current evidence on the diagnosis, prevention, pharmacological treatment, and long-term management of osteoporosis in adults. Methods: PubMed/MEDLINE and reference lists of major guidelines, position statements, systematic reviews, meta-analyses, and pivotal randomized trials were searched, with emphasis on evidence published from 2022 to 2026 and inclusion of older landmark trials when clinically relevant. Findings: Contemporary assessment integrates dual-energy X-ray absorptiometry (DXA) with fracture history, clinical risk factors, FRAX, vertebral imaging, and evaluation for secondary causes. Prevention combines adequate nutrition, correction of vitamin D deficiency, exercise, fall prevention, smoking cessation, and avoidance of excessive alcohol. Bisphosphonates and denosumab remain major antiresorptive therapies, whereas teriparatide, abaloparatide, and romosozumab are important options for selected patients at very high fracture risk. Treatment sequencing and planned antiresorptive therapy after anabolic treatment or denosumab discontinuation are central to long-term care. Conclusions: Osteoporosis management should be individualized according to absolute and imminent fracture risk. The principal therapeutic goal is prevention of fragility fractures and preservation of function rather than improvement in BMD alone.
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessOSTEOPOROSIS IN ADULTS: DIAGNOSIS, PREVENTION, AND TREATMENT – A NARRATIVE REVIEW
Objective: To synthesize current evidence on the diagnosis, prevention, pharmacological treatment, and long-term management of osteoporosis in adults. Methods: PubMed/MEDLINE and reference lists of major guidelines, position statements, systematic reviews, meta-analyses, and pivotal randomized trials were searched, with emphasis on evidence published from 2022 to 2026 and inclusion of older landmark trials when clinically relevant. Findings: Contemporary assessment integrates dual-energy X-ray absorptiometry (DXA) with fracture history, clinical risk factors, FRAX, vertebral imaging, and evaluation for secondary causes. Prevention combines adequate nutrition, correction of vitamin D deficiency, exercise, fall prevention, smoking cessation, and avoidance of excessive alcohol. Bisphosphonates and denosumab remain major antiresorptive therapies, whereas teriparatide, abaloparatide, and romosozumab are important options for selected patients at very high fracture risk. Treatment sequencing and planned antiresorptive therapy after anabolic treatment or denosumab discontinuation are central to long-term care. Conclusions: Osteoporosis management should be individualized according to absolute and imminent fracture risk. The principal therapeutic goal is prevention of fragility fractures and preservation of function rather than improvement in BMD alone.
- Open Access
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
THE ROLE OF SLEEP IN THE PATHOGENESIS OF OBESITY AND OBSTRUCTIVE SLEEP APNEA IN ADULTS: A SYSTEMATIC REVIEW
Obesity and obstructive sleep apnea (OSA) are common, clinically important and mutually reinforcing conditions associated with metabolic, cardiovascular and respiratory morbidity. Although obesity is widely recognized as a major modifiable risk factor for OSA, the relationship between sleep, weight regulation and sleep-disordered breathing is not limited to mechanical narrowing of the upper airway. The aim of this systematic review was to synthesize current evidence on the role of sleep duration, sleep quality, circadian disruption and sleep fragmentation in the pathogenesis of obesity and adult OSA. Scientific publications indexed in PubMed were reviewed, with priority given to systematic reviews, meta-analyses, prospective cohort studies, randomized controlled trials and major clinical reviews. The evidence indicates that short sleep duration is associated with future obesity and central obesity, while experimental sleep restriction promotes increased energy intake, impaired insulin sensitivity and adverse metabolic changes. Obesity contributes to OSA through upper-airway soft tissue enlargement, reduced lung volumes, increased pharyngeal collapsibility and altered ventilatory control. Conversely, OSA may worsen metabolic dysfunction through intermittent hypoxia, sleep fragmentation, sympathetic activation, oxidative stress and inflammation. These findings support a bidirectional model in which insufficient sleep, obesity and OSA interact through behavioral, endocrine, inflammatory and respiratory mechanisms. Adult patients with obesity should therefore be routinely assessed for sleep health and OSA risk, while OSA management should include weight and metabolic strategies in addition to airway-directed therapy.
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessTHE ROLE OF SLEEP IN THE PATHOGENESIS OF OBESITY AND OBSTRUCTIVE SLEEP APNEA IN ADULTS: A SYSTEMATIC REVIEW
Obesity and obstructive sleep apnea (OSA) are common, clinically important and mutually reinforcing conditions associated with metabolic, cardiovascular and respiratory morbidity. Although obesity is widely recognized as a major modifiable risk factor for OSA, the relationship between sleep, weight regulation and sleep-disordered breathing is not limited to mechanical narrowing of the upper airway. The aim of this systematic review was to synthesize current evidence on the role of sleep duration, sleep quality, circadian disruption and sleep fragmentation in the pathogenesis of obesity and adult OSA. Scientific publications indexed in PubMed were reviewed, with priority given to systematic reviews, meta-analyses, prospective cohort studies, randomized controlled trials and major clinical reviews. The evidence indicates that short sleep duration is associated with future obesity and central obesity, while experimental sleep restriction promotes increased energy intake, impaired insulin sensitivity and adverse metabolic changes. Obesity contributes to OSA through upper-airway soft tissue enlargement, reduced lung volumes, increased pharyngeal collapsibility and altered ventilatory control. Conversely, OSA may worsen metabolic dysfunction through intermittent hypoxia, sleep fragmentation, sympathetic activation, oxidative stress and inflammation. These findings support a bidirectional model in which insufficient sleep, obesity and OSA interact through behavioral, endocrine, inflammatory and respiratory mechanisms. Adult patients with obesity should therefore be routinely assessed for sleep health and OSA risk, while OSA management should include weight and metabolic strategies in addition to airway-directed therapy.
- Open Access
- 27 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
WHY IS PULMONARY EMBOLISM STILL MISSED? CLINICAL PITFALLS, DIAGNOSTIC ERRORS AND CONTEMPORARY STRATEGIES FOR EARLY RECOGNITION - REVIEW
Pulmonary embolism (PE) remains a frequent, potentially fatal and persistently challenging diagnosis in emergency, inpatient and primary care settings. Although modern diagnostic pathways combine pre-test probability assessment, D-dimer testing and imaging, PE is still missed or diagnosed late because its presentation overlaps with pneumonia, chronic obstructive pulmonary disease exacerbation, acute coronary syndrome, heart failure, anxiety and other common conditions. This review synthesizes evidence on why PE continues to be under-recognized and how diagnostic pathways can be improved. The manuscript was developed on the basis of contemporary scientific literature, including clinical practice guidelines, clinical reviews, prospective studies, and studies evaluating diagnostic delay. The available evidence suggests that delayed recognition of pulmonary embolism is rarely caused solely by limited access to imaging studies. More often, it results from low initial clinical suspicion, atypical presentation, cognitive errors, inappropriate use of D-dimer testing, inconsistent application of clinical prediction rules, and limitations of imaging modalities.. Age-adjusted and clinical probability-adjusted D-dimer strategies, the YEARS algorithm and PEGeD approach reduce unnecessary imaging while maintaining diagnostic safety in selected patients. Future improvement depends on combining disciplined bedside reasoning with validated algorithms, targeted use of imaging, clinician education, and carefully evaluated artificial intelligence or electronic health record decision-support tools.
- 27 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessWHY IS PULMONARY EMBOLISM STILL MISSED? CLINICAL PITFALLS, DIAGNOSTIC ERRORS AND CONTEMPORARY STRATEGIES FOR EARLY RECOGNITION - REVIEW
Pulmonary embolism (PE) remains a frequent, potentially fatal and persistently challenging diagnosis in emergency, inpatient and primary care settings. Although modern diagnostic pathways combine pre-test probability assessment, D-dimer testing and imaging, PE is still missed or diagnosed late because its presentation overlaps with pneumonia, chronic obstructive pulmonary disease exacerbation, acute coronary syndrome, heart failure, anxiety and other common conditions. This review synthesizes evidence on why PE continues to be under-recognized and how diagnostic pathways can be improved. The manuscript was developed on the basis of contemporary scientific literature, including clinical practice guidelines, clinical reviews, prospective studies, and studies evaluating diagnostic delay. The available evidence suggests that delayed recognition of pulmonary embolism is rarely caused solely by limited access to imaging studies. More often, it results from low initial clinical suspicion, atypical presentation, cognitive errors, inappropriate use of D-dimer testing, inconsistent application of clinical prediction rules, and limitations of imaging modalities.. Age-adjusted and clinical probability-adjusted D-dimer strategies, the YEARS algorithm and PEGeD approach reduce unnecessary imaging while maintaining diagnostic safety in selected patients. Future improvement depends on combining disciplined bedside reasoning with validated algorithms, targeted use of imaging, clinician education, and carefully evaluated artificial intelligence or electronic health record decision-support tools.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
ANTIBIOTIC OVERUSE IN RHINOSINUSITIS AND ITS ASSOCIATED RISKS - REVIEW
Rhinosinusitis is a common condition, affecting a large number of patients. In the vast majority of cases, the origin is viral. Results of the studies included in this article indicate that only 0.5-2% of all cases have bacterial etiology. Despite these facts, antibiotics are still widely prescribed for this condition. The aim of this study is to examine antibiotic overuse in rhinosinusitis and potential consequences of this practice. This review paper was based on resources available in the PubMed database; articles were identified using the following keywords: “rhinosinusitis AND antibiotic resistance”, “rhinosinusitis AND antibiotic overuse” and “acute rhinosinusitis.”. All included articles were published between 2020-2026. Results indicate that overuse of antibiotics in rhinosinusitis is a common practice in many countries. Increasing antibiotic resistance, along with the spread of multi-drug resistant microbes is one of the major consequences. Recent findings highlight the role of the respiratory microbiota and indicate that antibiotic therapy induces long-term changes in the nasal microbiome. Research shows that there are no significant differences in clinical effectiveness between amoxicillin and amoxicillin-clavulanate. In conclusion, antibiotic overuse in rhinosinusitis is a prevalent trend and it poses an important problem of public health. Further research is needed to better understand this issue. The implementation of educational programs and development of clear treatment guidelines may help address this problem.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessANTIBIOTIC OVERUSE IN RHINOSINUSITIS AND ITS ASSOCIATED RISKS - REVIEW
Rhinosinusitis is a common condition, affecting a large number of patients. In the vast majority of cases, the origin is viral. Results of the studies included in this article indicate that only 0.5-2% of all cases have bacterial etiology. Despite these facts, antibiotics are still widely prescribed for this condition. The aim of this study is to examine antibiotic overuse in rhinosinusitis and potential consequences of this practice. This review paper was based on resources available in the PubMed database; articles were identified using the following keywords: “rhinosinusitis AND antibiotic resistance”, “rhinosinusitis AND antibiotic overuse” and “acute rhinosinusitis.”. All included articles were published between 2020-2026. Results indicate that overuse of antibiotics in rhinosinusitis is a common practice in many countries. Increasing antibiotic resistance, along with the spread of multi-drug resistant microbes is one of the major consequences. Recent findings highlight the role of the respiratory microbiota and indicate that antibiotic therapy induces long-term changes in the nasal microbiome. Research shows that there are no significant differences in clinical effectiveness between amoxicillin and amoxicillin-clavulanate. In conclusion, antibiotic overuse in rhinosinusitis is a prevalent trend and it poses an important problem of public health. Further research is needed to better understand this issue. The implementation of educational programs and development of clear treatment guidelines may help address this problem.